Phathom Pharmaceuticals (PHAT) Liabilities and Shareholders Equity (2018 - 2026)

Phathom Pharmaceuticals (PHAT) has reported Liabilities and Shareholders Equity for 9 consecutive years, with $327.1 million the latest figure, recorded in Q2 2026.

• In Q2 2026, Liabilities and Shareholders Equity rose 30.71% year-over-year to $327.1 million; the TTM figure through Jun 2026 stood at $1.1 billion (down 13.6% YoY), while the FY2025 annual figure was $259.1 million, down 31.5% from the prior year.
• Liabilities and Shareholders Equity advanced to $327.1 million in Q2 2026 per PHAT's latest filing, from $305.1 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $413.8 million in Q4 2023 and bottomed at $144.0 million in Q1 2023.
• Historically, Liabilities and Shareholders Equity has averaged $272.6 million across 5 years, with a median of $262.1 million in 2023.
• Annual changes were most pronounced in 2022 — Liabilities and Shareholders Equity tumbled 39.5% — and 2023, when it jumped 151.1%.
• Phathom Pharmaceuticals' Liabilities and Shareholders Equity stood at $164.8 million in 2022, then surged by 151.1% to $413.8 million in 2023, then declined by 8.58% to $378.3 million in 2024, then sank by 31.5% to $259.1 million in 2025, then gained by 26.21% to $327.1 million in 2026.
• Business Quant data shows PHAT's Liabilities and Shareholders Equity at $327.1 million in Q2 2026, $305.1 million in Q1 2026, and $259.1 million in Q4 2025.